MACC1 and cancer: These results were verified in additional cancer cell lines, HCT116/MACC1-GFP, RKO/MACC1-GFP, CaCo-2 and DLD-1 (Fig. 1B-C): AZD6244 treatment reduced cell migration in HCT116/MACC1-GFP to 65% (p < 0.001), in RKO/MACC1-GFP to 34% (p = 0.002), in CaCo-2 to 75% (p = 0.005) and in DLD-1 to 54% (p = 0.008).